



U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

RECEIVED  
OCT 28 2002  
TECH CENTER 1600 2600

<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		Docket Number: <b>1662/52602</b>	
Application Number <b>09/841,025</b>	Filing Date <b>April 24, 2001</b>	Examiner <b>E. M. Huang</b>	Art Unit <b>1625</b>
Invention Title <b>ZOLPIDEM HEMITARTRATE</b>		Inventors <b>Aronhime et al.</b>	
Address to: Commissioner for Patents Washington D.C. 20231			
<p>1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 35 U.S.C. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the following reference, and the International Search Report citing it, to the attention of the Examiner. This reference is listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).</p> <p>2. A copy of each patent, publication or other information listed on the modified PTO form 1449 is enclosed.</p> <p>3. Applicants' attorney certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of information disclosure statement.</p>			
Dated: <u>10/25/02</u>		By: <u>W. David Wallace</u> W. David Wallace (Reg. No. 42,210)  KENYON & KENYON 1500 K Street, N.W. Suite 700 Washington, DC 20005 (202) 220-4200 - Telephone (202) 220-4201 - Facsimile	